



ViraCor-IBT Laboratories Names Dr. Mark Roberts President and Chief Executive Officer

Lenexa, KS and Lee's Summit, MO– December 15, 2009 –ViraCor-IBT Laboratories has named diagnostics industry veteran Mark Roberts, Ph.D. as the company's President and Chief Executive Officer. Roberts assumed the position on November 30, 2009.

Laurence McCarthy, chairman of the ViraCor-IBT board of directors, commented: "Mark is a proven leader with more than 18 years of experience in the diagnostics products industry. His scientific background together with his diagnostics experience provides him with the appropriate perspective to lead our growing organization.

Roberts will oversee all business operations for ViraCor-IBT and guide the direction of the company's future endeavors by identifying specific areas for growth and expansion. As Roberts takes the helm, John Martin, who most recently served as President for ViraCor-IBT, will move into the role of Chief Operating Officer.

"I am honored to have the opportunity to serve as president and chief executive officer for the newly-merged ViraCor-IBT. These are two companies that have achieved considerable success separately, and combined, the possibilities are endless," said Roberts. "I look forward to working with the executive team and board to not only continue to improve the combined company's abilities to serve our current customers, but also to provide new tests, capabilities and knowledge to an expanding group of healthcare professionals and drug developers."

ViraCor Laboratories and IBT Laboratories, both located in the greater Kansas City area, merged in June 2009 to form a unique specialty diagnostics laboratory. The combined company serves healthcare providers, researchers and drug developers nationwide, specializing in allergy, immunology and infectious disease testing.

Prior to joining ViraCor-IBT, Roberts served as general manager for Thermo Fisher Scientific's Seradyn business unit. During Roberts' tenure, the company became a leading developer and supplier of high-quality niche immunoassays for the Therapeutic Drug Monitoring field and forged several meaningful partnerships with pharmaceutical companies for the development of exclusive assays. He received his Ph.D. from Nottingham University in the United Kingdom.

For more information on ViraCor-IBT Laboratories and the company's testing menu, please visit www.viracor-ibt.com.

About ViraCor-IBT Laboratories

ViraCor Laboratories and IBT Laboratories merged in June 2009 to form a unique specialty diagnostics laboratory. The combined company specializes in cellular, immunology and allergy testing services as well as molecular assays that detect and monitor microbial pathogens. The company serves physicians, hospitals, commercial laboratories and biopharmaceutical companies nationwide. For more information, visit www.viracor-ibt.com.

Media Contact:

Amy Asper, Seigenthaler Public Relations
(615) 327-7999, aasper@seigenthaler.com